ARS Pharmaceuticals
SPRY
150 hedge funds and large institutions have $928M invested in ARS Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 58 increasing their positions, 23 reducing their positions, and 12 closing their positions.
300% more first-time investments, than exits
New positions opened: 48 | Existing positions closed: 12
152% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 23
74% more capital invested
Capital invested by funds: $533M → $928M (+$395M)
54% more call options, than puts
Call options by funds: $14.2M | Put options by funds: $9.25M
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
30% more funds holding
Funds holding: 115 → 150 (+35)
1.48% more ownership
Funds ownership: 64.59% → 66.08% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$8.38M |
| 2 |
FTM
First Turn Management
Del Mar,
California
|
+$7.06M |
| 3 |
DFO
Duquesne Family Office
New York
|
+$6.39M |
| 4 |
Morgan Stanley
New York
|
+$6M |
| 5 |
Millennium Management
New York
|
+$5.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$27.9M |
| 2 |
O
OrbiMed
New York
|
-$11.3M |
| 3 |
NI
Nextech Invest
Zurich,
Switzerland
|
-$9.48M |
| 4 |
PA
Perceptive Advisors
New York
|
-$7.38M |
| 5 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$5.44M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
RCMNY
151
Rubric Capital Management (New York)
New York
| – | -$5.44M | -639,203 | Closed |
|
|
SCM
152
Sio Capital Management
New York
| – | -$1.85M | -217,864 | Closed |
|
153
Walleye Capital
New York
| – | -$608K | -71,499 | Closed |
|
|
APP
154
Avantax Planning Partners
Dubuque,
Iowa
| – | -$274K | -32,174 | Closed |
|
|
SSA
155
Schonfeld Strategic Advisors
New York
| – | -$231K | -27,139 | Closed |
|
156
Los Angeles Capital Management
Los Angeles,
California
| – | -$231K | -27,120 | Closed |
|
|
AGM
157
Alpine Global Management
New York
| – | -$199K | -23,435 | Closed |
|
158
Arrowstreet Capital
Boston,
Massachusetts
| – | -$127K | -14,967 | Closed |
|
159
Voloridge Investment Management
Jupiter,
Florida
| – | -$88.4K | -10,388 | Closed |
|
160
Principal Financial Group
Des Moines,
Iowa
| – | -$87.1K | -10,230 | Closed |
|
161
Pacer Advisors
Malvern,
Pennsylvania
| – | -$4.13K | -485 | Closed |
|
|
C
162
Covestor
London,
United Kingdom
| – | -$12 | -1 | -8% |
|
SPRY Hedge Fund Activity: Q3 2024 in Review
150 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in ARS Pharmaceuticals (SPRY) for Q3 2024, worth a combined $928M — up 74% from $533M a quarter earlier.
Buyers outnumbered sellers: 48 funds opened new SPRY positions and 12 closed out — a net gain of 36 holders — while 58 added to existing stakes and 23 trimmed.
The largest buyer was Woodline Partners, adding an estimated $8.38M. The largest seller was K2 Principal Fund, cutting an estimated $27.9M.
- 150 institutional investors held ARS Pharmaceuticals (SPRY) as of Q3 2024, up from 115 in Q2 2024.
- Funds reported $928M of ARS Pharmaceuticals stock for Q3 2024, up 74% quarter-over-quarter.
- 48 funds opened new ARS Pharmaceuticals positions in Q3 2024 and 12 closed out, a net change of +36 holders.
- The largest ARS Pharmaceuticals buyer in Q3 2024 was Woodline Partners, an estimated $8.38M added.
- The largest ARS Pharmaceuticals seller in Q3 2024 was K2 Principal Fund, an estimated $27.9M sold.
Based on aggregated 13F filings for Q3 2024.